On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

Daratumumab, Carfilzomib, and Dexamethasone Combination Improves PFS in Patients with Relapsed/Refractory Multiple Myeloma

Adding daratumumab to the standard two-drug combination of carfilzomib and dexamethasone (KdD) led to a 37% improvement in progression-free survival (PFS), compared with carfilzomib...

QUAZAR: Oral Azacitidine Maintenance Improves Survival in Transplant-Ineligible AML

According to research presented as a late-breaking abstract at the 2019 ASH Annual Meeting, treatment with CC-486, an oral formulation of the hypomethylating agent...

Is Blinatumomab a New Standard of Care for Young Patients With B-Cell ALL?

Compared with standard chemotherapy, blinatumomab as consolidation prior to hematopoietic cell transplantation (HCT) is associated with fewer severe toxicities, higher response rates, and longer...

KTE-X19: A CAR T-Cell Option for Mantle Cell Lymphoma?

Ninety-three percent of patients with relapsed/refractory mantle cell lymphoma (MCL) responded to treatment with KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy,...

Clarithromycin Improves Responses But Fails to Prolong Survival in Newly Diagnosed Myeloma

Adding clarithromycin to lenalidomide plus dexamethasone improved the response rate in patients with multiple myeloma (MM), compared with lenalidomide and dexamethasone (Rd) alone. However,...

Bomedemstat Reduces Symptom Burden for Patients With Myelofibrosis

Bomedemstat improved symptoms in most patients with myelofibrosis, with no dose-limiting toxicities or progressions to acute myeloid leukemia, according to results from the first...

Mosunetuzumab Induces Durable Complete Remissions in Patients With B-Cell Non-Hodgkin Lymphoma

The bispecific monoclonal antibody mosunetuzumab, which targets CD3 and CD20, led to durable responses in patients with B-cell non-Hodgkin lymphoma (NHL), even in those...

DDGP Versus SMILE: Comparing Regimens for Extranodal Natural Killer T-Cell Lymphoma

In patients with extranodal natural killer T-cell lymphoma (ENKTL), treatment with the chemotherapy regimen of dexamethasone, cisplatin, gemcitabine, and peg-asparaginase (DDGP) improved survival compared...

Romiplostim Improves Platelet Counts, Chemotherapy Adherence in Patients With Chemotherapy-Induced Thrombocytopenia

Patients with cancer who develop chemotherapy-induced thrombocytopenia (CIT) often require delays, reductions, or discontinuations of treatment, but romiplostim appeared to allow patients to stay...

Nivolumab Monotherapy Successfully Bridges Patients With Refractory and Relapsed Hodgkin Lymphoma to AHCT

In a large proportion of patients with relapsed or refractory Hodgkin lymphoma (HL), nivolumab monotherapy was an effective bridge therapy to autologous hematopoietic cell...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.